Arix Bioscience plc
Director/PDMR Shareholding
Arix Bioscience plc (the "Company") today announces the annual award of nil cost options to Interim CEO Robert Lyne, which are subject to performance conditions over a three-year assessment period, in accordance with the Company's Remuneration Policy.
PDMR DEALING NOTIFICATION
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
a)
|
Name
|
Robert Lyne
|
2
|
Reason for the notification
|
a)
|
Position / status
|
Interim Chief Executive Officer
|
b)
|
Initial notification /
Amendment
|
Initial Notification
|
3
|
Details of issuer
|
a)
|
Name
|
Arix Bioscience plc
|
b)
|
LEI
|
213800OVT3AHQCXNIX43
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
a)
|
Description of the financial instrument, type of instrument
|
Ordinary Shares of Arix Bioscience plc
|
Identification code
|
GB00BD045071
|
b)
|
Nature of the transaction
|
Award of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP")
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
Nil
|
352,335
|
d)
|
Aggregated information
|
Aggregated price
|
Aggregated volume
|
N/A (single transaction)
|
N/A (single transaction)
|
e)
|
Date of the transaction
|
13 August 2021
|
f)
|
Place of the transaction
|
Outside a trading venue
|
For further information please contact:
Optimum Strategic Communications
Mary Clark, Manel Mateus
+44 (0)20 8078 4357
optimum.arix@optimumcomms.com
- Ends -